NEW YORK, United States — Moderna shares surged in U.S. trading on Wednesday after the company and Merck reported positive Phase 3 results for their personalised mRNA cancer vaccine, Intismeran, in combination with Keytruda for melanoma patients. The breakthrough trial result also lifted Merck shares and became the standout development among several major premarket stock movers.